These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30446652)

  • 61. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
    Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
    Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
    Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
    Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
    Santarpia L; Bottai G
    Curr Pharm Des; 2013; 19(5):864-82. PubMed ID: 22973956
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 65. BAY 43-9006 inhibition of oncogenic RET mutants.
    Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
    J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
    Vitagliano D; Carlomagno F; Motti ML; Viglietto G; Nikiforov YE; Nikiforova MN; Hershman JM; Ryan AJ; Fusco A; Melillo RM; Santoro M
    Cancer Res; 2004 Jun; 64(11):3823-9. PubMed ID: 15172989
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
    Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
    Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
    Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
    Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
    Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
    Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
    Beaudry P; Nilsson M; Rioth M; Prox D; Poon D; Xu L; Zweidler-Mckay P; Ryan A; Folkman J; Ryeom S; Heymach J
    Mol Cancer Ther; 2008 Feb; 7(2):418-24. PubMed ID: 18245671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Response to RET-Specific Therapy in
    Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
    Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
    [No Abstract]   [Full Text] [Related]  

  • 77. Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas.
    Krishnan A; Berthelet J; Renaud E; Rosigkeit S; Distler U; Stawiski E; Wang J; Modrusan Z; Fiedler M; Bienz M; Tenzer S; Schad A; Roth W; Thiede B; Seshagiri S; Musholt TJ; Rajalingam K
    Nat Commun; 2020 Apr; 11(1):2056. PubMed ID: 32345963
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
    Wang C; Mayer JA; Mazumdar A; Brown PH
    Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
    Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
    Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
    [No Abstract]   [Full Text] [Related]  

  • 80. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.